Hi readers,
For years, feline cancer treatment has existed in the shadows, based largely on slightly modified canine treatments.
This might finally be changing. A new study has just been published that sets out the genetic architecture of feline cancers more clearly than ever before.
Not wanting to sound overly breathless, but Feline Business Brief is hopeful that this new oncogenome study will give feline cancer R&D a solid shove forward.
It also raises a bigger question: will we finally see the arrival of precision medicine in cats?
What we’re watching
Why the feline oncogenome study matters for the future of cat health
Cancer is one of the leading causes of death in older cats, with approximately one in five dying from the disease.
And yet, in stark contrast to human or even canine medicine, the genomic structures of feline tumours have remained largely upmapped.
This, in turn, has significant implications for feline health and medicine. Without genomic maps, it is not possible to develop precision diagnostics or targeted therapies.
Last month, Science journal published “The oncogenome of the domestic cat,” a large-scale study sequencing nearly 500 feline tumours across 13 cancer types. For the first time, we have a systematic map of the domestic cat oncogenome.
One pivotal finding, which may have substantial implications for feline health: many of the same driver mutations seen in human cancers, also appear in cats.
Key findings:
Striking similarity in mutational patterns for specific cancer types. In feline mammary carcinomas, mutations in FBXW7 and PIK3CA were prevalent, closely resembling human breast cancer development;
High frequency of TP53 mutations, a gene also heavily implicated in human cancers. In cats, approximately one-third of tumours had TP53 alterations, closely mirroring rates seen in humans.
Recurrent mutations included loss of genes like PTEN and FAS or MYC, indicating that many of the fundamental pathways driving tumours are conserved across humans and cats.
Why this could be critical for feline health
Feline oncology has been limited by three main factors:
Limited feline genomic oncology mapping.
Feline cancer has been significantly under-studied compared to human and canine oncology.
This is despite cancer being a leading cause of death in older cats, and cats sharing many environmental (carcinogenic) exposures with humans. There is a lack of large-scale genomic analyses to guide feline diagnostics or therapeutics.
Dogs, on the other hand, are much more often used in translational research, i.e. to determine whether treatments effective in canine cancers could also be investigated
For example, one large Vet-OncoNet analysis of 16,272 veterinary cancer published in 2022 found dogs accounted for approximately 80% of entries (13,006) while cats made up just 20% (3,266).
Meanwhile, cats demonstrate a much higher proportion of malignant tumours (78.7% v 46.2% in dogs).
What's changed: The latest study on the feline oncogenome validates domestic cats as a comparative model for translational research.
High R&D costs relative to feline market size
A common argument for pharmaceutical companies’ overwhelming focus on canines is that cats represent a smaller potential market size, with less scope for variations in dosage. This would make feline R&D and pharma manufacturing more expensive for cats relative to dogs.
What’s changed: the discovery of mutations shared by both human and feline tumours indicates that development of feline-specific therapeutics might not need to start from scratch.
For example, in human oncology, PIK3CA mutations are actionable with targeted treatments, suggesting that these might eventually be explored in cats.
Lack of precision diagnostics for feline cancers
Precision medicine is much more developed for dogs than for cats, as far more is known about canine tumours.
What’s changed: Again, the oncogenome study has provided specific targets for diagnostics to aim at.
Implications for the feline market
Increased demand for feline diagnostics
If feline tumour mutations can be reliably linked to prognosis or treatment response, this may lead to growth in diagnostics tailored to feline oncology.
Targeted therapeutics
Rather than broad-spectrum chemotherapy, the opportunity may lie in repurposing or adapting pathway-specific compounds (see sidebar below).
Increased strategic attention to feline health
Investment in feline therapeutics has historically lagged behind dogs. A more comprehensive genomic map could shift the perception of feline health from ‘niche segment’ to an underserved growth market.
The broader pattern
Interest in feline health is on the rise (and we’re here for it!)
Over the past 12 months, we’ve seen several signs of increased interest in R&D into feline therapeutics:
Increased attention to feline obesity therapeutics (i.e. the feline GLP-1 race);
Greater investment into feline longevity (i.e. The Cat Health Company raised a milestone US$1.2 million in late 2025);
More interest generally in underserved cat categories (this is what spurred the creation of Feline Business Brief).
The oncogenome paper also fits into this broader pattern: the piecing-togetherof the basic data that make therapeutic R&D less speculative.
Feline health has often lacked the data that attract capital. While the expansion of feline R&D may prove gradual, this latest study will likely spur increased interest and potentially investment into feline health.
Who Is developing feline cancer treatments?
There are very few feline-labelled oncology drugs. Most oncology products in companion animals are:
Approved for dogs;
Used off-label in cats;
Or in early-stage translational research.
Company | Marketed oncology treatments (Brand / API) | Label species | Feline relevance signal |
Zoetis | Palladia® (toceranib phosphate) | Dog (MCT) | High: Palladia widely used off-label in cats (mast cell tumours, others) |
Laverdia-CA1 (verdinexor) | Dog (lymphoma) | Medium: mechanistic interest for feline lymphoma, no cat label | |
Elanco | Tanovea®-CA1 (rabacfosadine) | Dog (lymphoma) | Medium: canine focus, limited feline data |
Merck Animal Health | (No dedicated small-molecule feline oncology drug) | — | Low–Medium: oncology capability but no cat-labelled drug |
Boehringer Ingelheim | (No dedicated oncology therapeutic marketed for cats) | — | Low–Medium: No obvious feline oncology focus |
Dechra | Supportive oncology therapies (e.g., corticosteroids, chemo adjuncts) | Multi-species | Low: more supportive care |
VetDC | Investigational kinase inhibitors (e.g., VDC-1101 legacy links to Tanovea development) | Dog focus | Medium: small biotech flexibility |
Implications for feline oncology pipeline strategy:
Prioritising of tumour mutations common to humans and cats
For example, drugmakers such as Zoetis that already have small-molecule kinase inhibitors (TKIs) could consider expanding their pipeline to focus specifically on feline indications. Zoetis’ Palladia (toceranib phosphate), for example, is a TKI.
The diagnostics - therapeutics relationship
A lot depends on whether the mutations within feline cancers can be identified as clusters, which would make precision oncology in cats a worthwhile investment for diagnostics companies.
If so, growth in feline diagnostics would facilitate the development of targeted cancer therapies for cats.
Market size & demand
Overall though, cats still face significantly lower access to veterinary care compared to dogs, as well as lower spend per patient.
A lot therefore relies on whether feline-specific oncology treatments would be commercially viable (and affordable).
Feline Business Brief provides market intelligence on the global feline economy. We analyse early signals, emerging risks and structural shifts across feline nutrition, health, therapeutics, diagnostics, technology and retail.